Since MorphoSys AG (NASDAQ:MOR) and Midatech Pharma Plc (NASDAQ:MTP) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation of both companies.
Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys AG N/A 0.00 N/A -0.26 0.00 Demonstrates MorphoSys AG and Midatech Pharma Plc earnings per share (EPS), gross revenue and valuation.
Table 2 provides the return on equity, return on assets and net margins of the two firms.
Institutional and Insider Ownership
MorphoSys AG and Midatech Pharma Plc has shares owned by institutional investors as follows: 7.42% and 0%. Competitively, insiders own roughly 70.71% of Midatech Pharma Plc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) MorphoSys AG -3.13% -6.2% 4.75% 2.34% 0% 8.13% Midatech Pharma Plc -22.31% -46.69% -68.97% -71.17% -81.6% -75.18% For the past year MorphoSys AG had bullish trend while Midatech Pharma Plc had bearish trend.
On 2 of the 2 factors MorphoSys AG beats Midatech Pharma Plc.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase III clinical trial for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL antibody directed against CD38, which is in Phase II trial for the treatment of multiple myeloma and other cancers. The company’s product pipeline also comprises MOR103/GSK3196165, a human HuCAL antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trial for treating rheumatoid arthritis and inflammatory hand osteoarthritis. In addition, its product pipeline includes MOR106, a human monoclonal antibody directed against IL-17C, which is in Phase I clinical trial for the treatment of atopic dermatitis; and MOR107 that is in preclinical investigation with a focus on oncology indications. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.
Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.
Click here to view original web page at Reviewing MorphoSys AG (MOR)’s and Midatech Pharma Plc (NASDAQ:MTP)’s results